Literature DB >> 21148651

Dose adjustment of anaesthetics in the morbidly obese.

J Ingrande1, H J M Lemmens.   

Abstract

Anaesthesiologists must be prepared to deal with pharmacokinetic and pharmacodynamic (PD) differences in morbidly obese individuals. As drug administration based on total body weight can result in overdose, weight-based dosing scalars must be considered. Conversely, administration of drugs based on ideal body weight can result in a sub-therapeutic dose. Changes in cardiac output and alterations in body composition affect the distribution of numerous anaesthetic drugs. With the exception of neuromuscular antagonists, lean body weight is the optimal dosing scalar for most drugs used in anaesthesia including opioids and anaesthetic induction agents. The increased incidence of obstructive sleep apnoea and fat deposition in the pharynx and chest wall places the morbidly obese at increased risk for adverse respiratory events secondary to anaesthetic agents, thus altering the PD properties of these drugs. Awareness of the pharmacology of the commonly used anaesthetic agents including induction agents, opioids, inhalation agents and neuromuscular blockers is necessary for safe and effective care of morbidly obese patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21148651     DOI: 10.1093/bja/aeq312

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  59 in total

1.  Determination of minimum alveolar concentration for isoflurane and sevoflurane in a rodent model of human metabolic syndrome.

Authors:  Dinesh Pal; Meredith E Walton; William J Lipinski; Lauren G Koch; Ralph Lydic; Steve L Britton; George A Mashour
Journal:  Anesth Analg       Date:  2011-12-13       Impact factor: 5.108

2.  Obesity and allometric scaling of pharmacokinetics.

Authors:  Douglas J Eleveld; Johannes H Proost; Anthony R Absalom; Michel M R F Struys
Journal:  Clin Pharmacokinet       Date:  2011-11-01       Impact factor: 6.447

3.  Optimal Drug Dosing in the Obese--Still Many Years Ahead.

Authors:  Ashish C Sinha; Preet Mohinder Singh
Journal:  Obes Surg       Date:  2015-11       Impact factor: 4.129

Review 4.  Optimizing care for the obese patient in interventional radiology.

Authors:  Dwight Aberle; Hearns Charles; Steven Hodak; Daniel O'Neill; Rahmi Oklu; Amy R Deipolyi
Journal:  Diagn Interv Radiol       Date:  2017 Mar-Apr       Impact factor: 2.630

5.  Upper Airway Elasticity Estimation in Pediatric Down Syndrome Sleep Apnea Patients Using Collapsible Tube Theory.

Authors:  Dhananjay Radhakrishnan Subramaniam; Goutham Mylavarapu; Keith McConnell; Robert J Fleck; Sally R Shott; Raouf S Amin; Ephraim J Gutmark
Journal:  Ann Biomed Eng       Date:  2015-08-28       Impact factor: 3.934

6.  Intraoperative Methadone in Same-Day Ambulatory Surgery: A Randomized, Double-Blinded, Dose-Finding Pilot Study.

Authors:  Helga Komen; L Michael Brunt; Elena Deych; Jane Blood; Evan D Kharasch
Journal:  Anesth Analg       Date:  2019-04       Impact factor: 5.108

Review 7.  Impact of obesity on drug metabolism and elimination in adults and children.

Authors:  Margreke J E Brill; Jeroen Diepstraten; Anne van Rongen; Simone van Kralingen; John N van den Anker; Catherijne A J Knibbe
Journal:  Clin Pharmacokinet       Date:  2012-05-01       Impact factor: 6.447

8.  Atropine sulfate for treatment of bradycardia in a patient with morbid obesity: what may happen when you least expect it.

Authors:  Michele Carron; Stefano Veronese
Journal:  BMJ Case Rep       Date:  2015-01-29

9.  Correction to: Pharmacokinetics of Fentanyl and Its Derivatives in Children: A Comprehensive Review.

Authors:  Victoria C Ziesenitz; Janelle D Vaughns; Gilbert Koch; Gerd Mikus; Johannes N van den Anker
Journal:  Clin Pharmacokinet       Date:  2018-03       Impact factor: 6.447

10.  Context-sensitive decrement times for inhaled anesthetics in obese patients explored with Gas Man®.

Authors:  Jonas Weber; Johannes Schmidt; Steffen Wirth; Stefan Schumann; James H Philip; Leopold H J Eberhart
Journal:  J Clin Monit Comput       Date:  2020-02-17       Impact factor: 2.502

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.